S&P 500 falls on pressure from retail stocks, weak jobless claims
Investing.com - Oppenheimer has reiterated an Outperform rating and $13.00 price target on Nyxoah SA (NASDAQ:NYXH) following the company’s second-quarter 2025 financial results. According to InvestingPro data, the stock is currently trading below its Fair Value, with analyst targets ranging from $12 to $14.
Nyxoah reported second-quarter revenue of €1.3 million, which excluded €0.7 million in deferred revenue. The results aligned with the company’s pre-release last week, matching consensus estimates of €1.3 million but falling short of Oppenheimer’s €1.5 million projection. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 3.59, though it’s currently experiencing rapid cash burn.
The company recently received full FDA approval for its Genio device, with the approved label covering moderate-to-severe OSA (Obstructive Sleep Apnea) with an Apnea-Hypopnea Index between 15 and 65.
Nyxoah has closed enrollment early in its ACCESS trial, expressing confidence that current implants will provide sufficient data to support adding Complete Concentric Collapse ( CCC (WA:CCCP)) to the product label.
Oppenheimer noted that field checks suggest slowing utilization growth with unilateral hypoglossal nerve stimulation (HGNS), and competition in the HGNS market is expected to intensify as Genio’s commercialization begins and with LIVN’s anticipated market entry in late second half of 2026. InvestingPro subscribers can access 8 additional key insights about Nyxoah’s financial health and market position through the comprehensive Pro Research Report, available exclusively on the platform.
In other recent news, Nyxoah SA reported a robust second quarter for 2025, highlighting significant revenue growth despite an operating loss. The company’s recent FDA approval for its GENIOR system has been a focal point for investors, contributing to optimism about its future prospects. Stifel has reiterated its Buy rating on Nyxoah, maintaining a $12.00 price target, and emphasized the importance of the FDA approval over the company’s preannounced second-quarter results. The firm noted that Nyxoah plans to launch its product in high-volume centers, specifically targeting the approximately 300 U.S. HGNS facilities that account for about 75% of the industry’s volume. These developments have underscored the company’s strategic advancements in the obstructive sleep apnea market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.